

## Best Pharmaceuticals for Children Act (BPCA) Priority List of Needs in Pediatric Therapeutics

The National Institutes of Health (NIH) hereby announces the BPCA Priority List of Needs in Pediatric Therapeutics for 2011.

### Update on BPCA Prioritization

The BPCA requires that the NIH identify the drugs of highest priority for study in pediatric populations. Part of the NIH mandate under the BPCA is to publish a list of drugs/needs in pediatric therapeutics. The first priority list of off-patent drugs needing further study under the 2002 BPCA legislation was published in January 2003 in the Federal Register (FR Vol. 68, No. 13; Tuesday, January 21, 2003: 2789-2790). After the BPCA reauthorization in 2007, a revised priority list of needs in pediatric therapeutics was published in April 2009 (FR Vol. 74, No. 70; Tuesday, April 14, 2009: 17203-17205) and revised in September 2009 (<http://bpca.nichd.nih.gov/about/process/upload/2009-Summary-091509-1-rev.pdf>). The legislation mandates that the NIH update the priority list every 3 years; this publication serves as an update to the BPCA priority list of needs in pediatric therapeutics.

In the transition from prioritizing drugs to prioritizing therapeutic needs, several changes have been implemented over the last year in refining the prioritization process. These include: the need for more up-front input to gather information on preliminary drugs (for example, information on frequency of use and frequency of condition) as well as expert input; a better approach for mass outreach; enhancement of NIH interagency collaborations; and improvement in the overall prioritization process.

The revised process includes:

- A systematic approach with clear objectives and outcomes
- Well-defined, objective criteria that are mutually exclusive and a of manageable number
- A dynamic process, including transparency, stakeholder input, and leadership
- Expert involvement to inform and contribute to the process.

For 2010, nominations for the BPCA Priority List of Needs in Pediatric Therapeutics were solicited through a Request for Information (RFI) announcement as a part of fulfilling the NIH's authority and responsibility to establish a program for pediatric drug testing and development as outlined in the BPCA legislation. The BPCA Priority List consists of key therapeutic needs in the medical treatment of children and adolescents; it is organized by therapeutic area, which can be a group of conditions, a subgroup of the population, or a setting of care. Each calendar year, a few therapeutic areas are selected for discussion and further prioritization. Below is a summary of the revised BPCA prioritization process:

- In early 2010, the RFI was issued to solicit nominations for future studies of pediatric therapeutics under BPCA.
- The *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) Obstetric and Pediatric Pharmacology Branch received 107 nominations, 67 of which met the criteria for review.

- All nominations were reviewed and evaluated on six key criteria, as follows:
  - Relevant to BPCA mission and goals
  - No disqualifying ethical concerns
  - Evidence: consideration of the level of evidence available and current gaps
  - Impact: potential effect on children, society, and delivery of care
  - Population: consideration of the different populations that may benefit from the research
  - Feasibility: consideration of the resources available to conduct the study.
- Twenty-two volunteer health professionals scored the 67 nominations according to evidence, impact, and the pediatric population affected. Each nomination was reviewed by a panel of three evaluators.
- Therapeutic area working groups were developed and met throughout 2010 to discuss the gaps in knowledge in the therapeutic approaches to diseases in gastroenterology, endocrinology, and neurology.
- Minutes of all working group meetings conducted under the BPCA can be found on the BPCA Web site (<http://bpca.nichd.nih.gov>).
- As a final step in the process, the NICHD, with input from the U.S. Food and Drug Administration (FDA), ranked the nominations based on the evaluators' scores, quality and quantity of existing studies, and feasibility of the proposed study. The result was a tiered list of nominations considered for prioritization. Tier One represents the highest percentage of scores: nominations of interest to the NICHD for prioritization. Tier Two represents the average percentage of scores: nominations of possible interest to the NICHD at a later time. Tier Three represents the lowest percentage of scores: nominations of least interest to the NICHD at this time for prioritization.

The NICHD sponsored the BPCA Annual Prioritization Meeting, held November 9–10, 2010, with stakeholders from the NIH, the FDA, the American Academy of Pediatrics and other pediatric organizations and societies, and patient advocates. The meeting allowed the NICHD to review the present progress from ongoing research and to discuss the proposed therapeutic areas from the 2010 nominations to be prioritized for future study under the BPCA and added to the existing BPCA priority list.

Below is an updated list of therapeutic areas and drugs that have been prioritized for study since the inception of the BPCA, which includes new areas of prioritization from Tier One nominations of the 2010 outreach, and a summary of the NICHD's plans and progress in all of these areas.

### **Priority List of Needs in Pediatric Therapeutics 2011**

In accordance with the BPCA legislation, the following list outlines priority needs in pediatric therapeutics for the therapeutic areas listed below.

- [Table 1: Infectious Disease Priorities](#)
- [Table 2: Cardiovascular Disease Priorities](#)
- [Table 3: Respiratory Disease Priorities](#)
- [Table 4: Intensive Care Priorities](#)
- [Table 5: Bio-defense Research Priorities](#)

- [Table 6: Pediatric Cancer Priorities](#)
- [Table 7: Psychiatric Disorder Priorities](#)
- [Table 8: Neurological Disease Priorities](#)
- [Table 9: Neonatal Research Priorities](#)
- [Table 10: Adolescent Research Priorities](#)
- [Table 11: Hematologic Disease Priorities](#)
- [Table 12: Endocrine Disease Priorities and Diseases with Limited Alternative Therapies](#)
- [Table 13: Dermatologic Disease Priorities](#)
- [Table 14: Gastrointestinal Disease Priorities](#)
- [Table 15: Renal Disease Priorities](#)
- [Table 16: Rheumatologic Disease Priorities](#)
- [Table 17: Special Considerations](#)

**Table 1. Infectious Disease Priorities**

Current or Proposed Listed Therapeutic Area	Current or Proposed Listed Drug	Gaps in Knowledge/ Labeling	Type of BPCA Study and/or Scientific Needs	Plans and Progress
Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) infections	Clindamycin	Optimal therapy and management of community-acquired skin and soft tissue infections	Pharmacokinetics (PK), safety, and efficacy clinical studies	Pediatric study under consideration by the Pediatric Trials Network (PTN)
	Trimethoprim-sulfamethoxazole	Biomarkers of disease	PK and efficacy (comparison) studies	Pediatric study under consideration by the PTN
Infections	Benzathine penicillin-G	Dosing in relation to body size	PK, safety, and efficacy clinical studies	Pediatric study under consideration by the PTN
	Acyclovir	Dosing, efficacy, and safety in infants and children with herpetic infections	PK, safety, and efficacy clinical studies	Pediatric study under consideration by the PTN
	Doxycycline	PK, safety in children younger than 8 years	PK, safety, and efficacy clinical studies	Pediatric study under consideration by the PTN
Tinea capitis	Griseofulvin	Safety and efficacy of higher doses in children <20 kg with tinea capitis	PK, efficacy, and safety of higher doses in young children	Written Request (WR) received from FDA; pediatric study under consideration by the PTN
Antituberculous (TB) drugs	No specific drug	Safety and efficacy; formulations	New efficacy studies for global health, formulations	NIH-FDA Formulations Platform Initiative 2010–2012
<b>Antiparasitic drugs</b>	<b>Albendazole</b>	<b>PK, safety, and efficacy for Toxocara infections</b>	<b>New efficacy studies for global health, formulations</b>	<b>NIH-FDA Formulations Platform Initiative 2010–2012</b>
Influenza	Oseltamivir	Pharmacoepidemiology data	Impact on clinical outcomes in hospitalized children with influenza	Current NICHD grant funding

Drug and indications **in bold** are newly added to the BPCA list from the 2010 prioritization process or other sources identified by NICHD as a priority.

[Back to Top](#)

**Table 2. Cardiovascular Disease Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Hypertension	Hydrochlorothiazide	PK, safety, and efficacy in obese adolescents	Comparison studies, PK studies	WR received from FDA; pediatric study under consideration by the PTN
	Beta blockers	PK, safety, and efficacy in obese adolescents	Comparison studies, PK studies	Pending
	<b>Lisinopril</b>	<b>PK in children with kidney transplant</b>	<b>PK, safety, and efficacy clinical studies; formulations</b>	Pediatric study under consideration by the PTN
	<b>Amlodipine</b>	<b>PK in children with kidney transplantation, formulations</b>	<b>PK, safety, and efficacy clinical studies</b>	Pediatric study under consideration by the PTN
Hypotension	Sodium nitroprusside	PK, safety, and efficacy	PK, short- and long-term safety and efficacy trials for controlled hypotension	WR received from FDA; both clinical trials completed, data analyses ongoing; clinical study report (CSR) to FDA Summer 2011
	Dopamine	Outcome measures in neonates and children treated for hypotension	Defining outcome measures	Collaborating with existing NICHD networks (Neonatal Research Network)
<b>Dyslipidemia</b>	<b>Statins</b>	<b>Risk/benefit profile of long-term use in children</b>	<b>Novel study designs, use of surrogate markers for determining the value of long-term statin use in children</b>	<b>Pending</b>

Drug and indications **in bold** are newly added to the BPCA list from the 2010 prioritization process or other sources identified by NICHD as a priority.

[Back to Top](#)

**Table 3. Respiratory Disease Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Asthma	Asthma therapeutics in young children	Objective measures of lung function and responses to therapy in children younger than 4 years	<b>Standardization of outcome measures in research</b>  <b>Identification of barriers to implementation of guidelines for asthma treatment</b>	Trans-NIH and trans-U.S. Department of Health and Human Services collaborations  Meeting on Asthma Outcome Measures held March 2010  Meeting on asthma disparities held December 2010.
	Drug delivery systems	Effectiveness of drug delivery systems used in children	<b>Use of hydrofluoroalkanes (HFAs) with inhaled corticosteroids in children younger than 4 years</b>	<b>Pending</b>
	Albuterol	Dose response, safety, and efficacy	Safety, efficacy, and appropriate mode of delivery in children in acute care settings	NICHD Collaborative Pediatric Critical Care Network data collection
<b>Pulmonary hypertension</b>	<b>No specific drug</b>	<b>Treatment strategies in children with pulmonary hypertension of differing etiologies (idiopathic versus secondary)</b>	<b>Outcome measures in children</b>	<b>Pending</b>

Drug and indications **in bold** are newly added to the BPCA list from the 2010 prioritization process or other sources identified by NICHD as a priority.

[Back to Top](#)

**Table 4. Intensive Care Priorities**

Current or Proposed Listed Therapeutic Area	Current or Proposed Listed Drug	Gaps in Knowledge/ Labeling	Type of BPCA Study and/or Scientific Needs	Plans and Progress
Anesthesia/sedation	Ketamine	Safety	Preclinical and clinical studies of short- and long-term effects	Preclinical studies under way with FDA/ National Center for Toxicological Research (NCTR)
	<b>Inhaled anesthetics/isoflurane</b>	<b>Toxicity of inhaled anesthetics in developing brains</b>	<b>Identification of markers of apoptosis</b>	Preclinical models, <i>in vitro</i> studies
	Lorazepam	Dosing, safety	PK, safety, and efficacy trial comparing lorazepam with midazolam for sedation	WR received from FDA; clinical trial completed; CSR for submission to FDA Spring 2011

Drug and indications **in bold** are newly added to the BPCA list from the 2010 prioritization process or other sources identified by NICHD as a priority.

[Back to Top](#)

**Table 5. Bio-defense Research Priorities**

Current or Proposed Listed Therapeutic Area	Current or Proposed Listed Drug	Gaps in Knowledge/ Labeling	Type of BPCA Study and/or Scientific Needs	Plans and Progress
Nerve agent exposure	Drug delivery systems	Need for pediatric auto-injectors		Pending
	<b>Midazolam</b>	<b>Dosing studies for treatment of seizures related to exposure</b>	<b>PK studies</b>	<b>Trans-NIH collaborations</b>
<b>Cyanide toxicity</b>	<b>Hydroxycobalamine</b>	<b>Dosing and effectiveness in inhalation injuries suffered during fires</b>	<b>Safety and efficacy</b>	Pediatric study under consideration by the PTN; real-time cyanide assay under development with the National Institute of Neurological Disorders and Stroke (NINDS)
Organophosphate poisoning	Pralidoxime	Dosing and safety		<b>Label changed September 2010</b>

Drug and indications **in bold** are newly added to the BPCA list from the 2010 prioritization process or other sources identified by NICHD as a priority.

[Back to Top](#)

**Table 6. Pediatric Cancer Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Neuroblastoma	13-cis-retinoic acid	New indication for neuroblastoma, pediatric formulation	PK studies, new formulation	Proposed Pediatric Study Request negotiated with FDA; WR received from FDA; collaboration with National Cancer Institute (NCI)/Children's Oncology Group (COG)
Leukemias and solid tumors	Methotrexate	Safety studies	Neurocognitive outcomes in young children with high-risk acute lymphoblastic leukemia	WR received from FDA; collaborations with NCI/COG; clinical trial ongoing
	Vincristine	PK and safety studies	PK modeling and safety studies to evaluate for neurotoxicity	WR received from FDA; collaborations with NCI/COG; clinical trial ongoing; Clinical and Translational Science Awards (CTSA) administrative supplement
	Daunomycin	PK studies	PK studies in children with elevated body mass index	WR received from FDA; collaborations with NCI/COG; study completed, CSR to FDA Spring 2011
	Actinomycin-D	PK and safety studies	PK modeling and simulation, data mining for safety (hepatotoxicity)	WR received from FDA; collaborations with NCI/COG; clinical trial ongoing
	<b>6-mercaptopurine</b>	<b>Formulations</b>		<b>NIH-FDA Formulations Platform</b>

Drug and indications **in bold** are newly added to the BPCA list from the 2010 prioritization process or other sources identified by NICHD as a priority.

[Back to Top](#)

**Table 7. Psychiatric Disorder Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Attention deficit and hyperactivity disorder (ADHD)	Methylphenidate	Safety and toxicity		Preclinical and clinical studies are ongoing with NCTR and the National Institute of Environmental Health Sciences
Bipolar disease	Lithium	PK, safety, and efficacy	Dosing and tolerance, short- and long-term safety	WR received from FDA; PK data submitted to FDA January 2010; safety and efficacy clinical trial ongoing
<b>Psychosis, aggression</b>	Atypical antipsychotics	Long-term safety—metabolic derangements	Comparative long-term safety, epidemiology research on frequency of use	<b>Translational research; outpatient epidemiology research effort under development</b>

Drug and indications **in bold** are newly added to the BPCA list from the 2010 prioritization process or other sources identified by NICHD as a priority.

[Back to Top](#)

**Table 8. Neurological Disease Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Cerebral palsy	Baclofen (oral)	PK, safety, and efficacy	PK and efficacy, pediatric formulation	WR received from FDA; clinical trial completed; CSR to FDA Spring 2011
	<b>Propranolol</b>	<b>Efficacy in prophylaxis</b>	<b>Efficacy in migraine prevention</b>	<b>Pending</b>
	<b>Amitriptyline</b>	<b>Efficacy in prophylaxis</b>	<b>Efficacy in migraine prevention</b>	<b>Pending</b>
Seizures	Lorazepam	PK, safety, and efficacy	PK, safety, and efficacy in treating status epilepticus	WR received from FDA; PK trial data submitted to FDA February 2009; safety and efficacy clinical trial under way
	<b>Fosphenytoin</b>	<b>PK, safety</b>	<b>PK, safety in treating seizures in young children</b>	<b>Pending</b>

Drug and indications **in bold** are newly added to the BPCA list from the 2010 prioritization process or other sources identified by NICHD as a priority.

[Back to Top](#)

**Table 9. Neonatal Research Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Neonatal bronchopulmonary dysplasia (BPD)/lung development	Betamethasone	Dosing, efficacy	Determination of dosing and effectiveness	Reviewing existing data; current NICHD grant funding
	Azithromycin (IV)	Dosing, efficacy	PK, efficacy in treating ureaplasma infections to prevent BPD	WR received from FDA; current NICHD grant funding
	Hydrochlorothiazide	Dosing, safety, and efficacy	Determination of dosing and effectiveness	Collaborations with the National Heart, Lung, and Blood Institute network data collection
Neonatal pain	Morphine	Pain	Optimization of dosing and biomarkers of pain in neonates	Current NICHD grant funding
Neonatal abstinence syndrome (NAS)	Methadone	PK, safety	Treatment strategies of NAS in opioid-exposed neonates	CTSA administrative supplement
<b>Infections in neonates</b>	<b>Metronidazole</b>	<b>PK and efficacy in neonates with abdominal infections</b>	<b>PK study</b>	<b>Pediatric study under consideration by the PTN</b>
	Ampicillin	PK and safety in very low birth weight neonates	PK, safety clinical studies	WR received from FDA; pediatric study under consideration by the PTN
Neonatal necrotizing enterocolitis (NEC)	Meropenem	PK, safety in neonates		WR received from FDA; clinical PK and safety trial completed; CSR to FDA Spring 2011

Drug and indications **in bold** are newly added to the BPCA list from the 2010 prioritization process or other sources identified by NICHD as a priority.

[Back to Top](#)

**Table 10. Adolescent Research Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Over-the-counter drug use	No specific drug	Health literacy		December 2007 symposia
<b>Adolescent pharmacology</b>	<b>No specific drug</b>	<b>Effects of puberty on PK/pharmacodynamics, adherence, and formulations research</b>	<b>Translational research, need to include adolescents in clinical trials</b>	<b>Pending</b>

Drug and indications **in bold** are newly added to the BPCA list from the 2010 prioritization process or other sources identified by NICHD as a priority.

[Back to Top](#)

**Table 11. Hematologic Disease Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Sickle cell anemia	Hydroxyurea	Safety and efficacy in young children	PK, safety, and efficacy  Oral formulation for children	WR received from FDA; BABY HUG trial completed in children 9–17 months of age, CSR in preparation; long-term safety follow-up study under way; PK and bioequivalence study under development
<b>Thrombosis and thromboprophylaxis</b>	<b>No specific drug</b>	<b>Treatment and prevention of childhood strokes and venous/arterial thrombosis</b>		<b>Pending</b>

Drug and indications **in bold** are newly added to the BPCA list from the 2010 prioritization process or other sources identified by NICHD as a priority.

[Back to Top](#)

**Table 12. Endocrine Disease Priorities and Diseases with Limited Alternative Therapies**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Fragile X	MGluR5 antagonists	Outcome measures targets for intervention	Development of MGluR5 antagonists to treat Fragile X	Development of new therapeutics cofunded with NINDS; clinical research under way
Type 1 diabetes	No specific drug	Immunomodulatory therapies	Development of novel immunomodulatory therapies for children with type 1 diabetes	Collaborations with existing NIH networks

Drug and indications **in bold** are newly added to the BPCA list from the 2010 prioritization process or other sources identified by NICHD as a priority.

[Back to Top](#)

**Table 13. Dermatologic Disease Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Atopic dermatitis	Hydrocortisone valerate	Effects on growth and hypothalamic-pituitary-adrenal axis suppression	Long-term safety data in children younger than 2 years	Pending
<b>Severe inflammatory skin disease</b>	<b>Methotrexate</b>	<b>Dosing, efficacy, and safety</b>	<b>Safety and efficacy in treatment of severe inflammatory disease</b>	<b>Pending</b>

Drug and indications **in bold** are newly added to the BPCA list from the 2010 prioritization process or other sources identified by NICHD as a priority.

[Back to Top](#)

**Table 14. Gastrointestinal Disease Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Gastroesophageal reflux	<b>Prokinetic drugs</b>	<b>New drugs; dosing, safety, and efficacy of existing drugs in neonates and infants</b>	<b>Effectiveness and outcome measures in young children</b>	<b>Pending</b>
	<b>H2 blockers</b>	<b>Dosing and efficacy data</b>	<b>Safety and effectiveness in infants</b>	<b>Pending</b>
<b>Cyclic vomiting and weight gain</b>	<b>Cyproheptadine</b>	<b>Dosing, efficacy, and safety</b>		<b>Pending</b>
<b>Cholestatic disease</b>	<b>Ursodeoxycholic acid</b>	<b>Safety and efficacy in young children</b>		<b>Pending</b>

Drug and indications **in bold** are newly added to the BPCA list from the 2010 prioritization process or other sources identified by NICHD as a priority.

[Back to Top](#)

**Table 15. Renal Disease Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Chronic kidney failure	Devices used in dialysis	Drug distribution, elimination, and accumulation in continuous renal replacement therapy	Device validation studies in children on chronic renal replacement therapy	Pending
<b>Anemia of chronic kidney disease</b>	<b>Agents to stimulate erythropoiesis</b>	<b>Optimal PK, efficacy, and safety</b>	<b>Appropriate dosing and outcome measures in children with chronic kidney disease</b>	<b>Pending</b>

Drug and indications **in bold** are newly added to the BPCA list from the 2010 prioritization process or other sources identified by NICHD as a priority.

[Back to Top](#)

**Table 16. Rheumatologic Disease Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Connective tissue disorders	Hydroxychloroquine	PK and safety in children with juvenile idiopathic arthritis	PK, safety studies	Pending

Drug and indications in **bold** are newly added to the BPCA list from the 2010 prioritization process or other sources identified by NICHD as a priority.

[Back to Top](#)

**Table 17. Special Considerations**

<b>Area of Consideration</b>	<b>Identified Therapeutic Area</b>	<b>Gaps in Knowledge/Labeling</b>	<b>Type of Study and/or Scientific Needs</b>
<b>Therapeutics in children with intellectual and developmental disabilities</b>	<b>No specific drug or indication</b>	<b>Identification of differences in drug disposition and response, including safety and efficacy outcome measures</b>	<b>Need for routine inclusion in clinical trials</b>
<b>Pediatric formulations</b>	<b>Multiple drugs and indications:</b>  <b>Infectious diseases:</b> <b>HIV: antiretrovirals</b> <b>Tuberculosis: isoniazid</b> <b>Trypanosomiasis:</b> <b>benznidazole,</b> <b>nifurtimox</b> <b>Parasitic infections:</b> <b>albendazole</b> <b>Malaria: mefloquine,</b> <b>sulfadoxine-pyrimethamine,</b> <b>chlorproguanil-dapsone</b>  <b>Hematology: hydroxyurea</b>  <b>Oncology:</b> <b>6-mercaptopurine,</b> <b>methotrexate,</b> <b>prednisone,</b> <b>isotretinoin</b>  <b>Spasticity: baclofen</b>  <b>Hypothyroidism:</b> <b>l-thyroxine</b>	<b>Taste-masking technologies</b>  <b>Orally dissolvable dosage forms that do not require water</b> <b>Heat-stable and light-stable dosage forms</b>  <b>Safety data for excipients</b>	<b>Improving the technology and designs of child-friendly/easy-to-swallow dosage forms of drugs to improve adherence and effectiveness</b>  <b>NIH-FDA Formulations Platform</b>
<b>Pediatric devices</b>	<b>General Issues</b>	<b>Need for validation of existing devices used in children</b>	<b>Pending</b>

	<b>Neonatal hypoxic ischemic encephalopathy (HIE)</b>  <b>Increased intracranial pressure</b>  <b>Sleep disordered breathing</b>	<b>Brain cooling in conjunction with neuroprotective drugs to prevent HIE</b>  <b>Cerebrospinal fluid (CSF) shunts</b>  <b>Continuous positive airway pressure (CPAP) and nasal devices</b>	<b>Comparison study of the effectiveness of brain-cooling devices with drugs</b>  <b>Improved designs for CSF shunts for hydrocephalus</b>  <b>Development of home-based nasal devices and CPAP machines for positive pressure ventilation in toddlers and infants</b>
--	--	---	--

Drug and indications **in bold** are newly added to the BPCA list from the 2010 prioritization process or other sources identified by NICHD as a priority.

[Back to Top](#)

**Table 18: Current List of Drugs Evaluated for BPCA Listing and Being Considered for Future Prioritization (Tier Two)**

<b>Drug</b>	<b>Indication</b>	<b>Year evaluated</b>
Erythropoietin	Neonatal brain injury	2010
Bevacizumab	Retinopathy of prematurity	2010
CC10, a novel anti-inflammatory agent	BPD long-term outcomes	2010
Gastrojejunal feeding tubes with larger jejunal port	Short gut syndrome	2010
Miralax	Treatment of constipation in young children	2010
Megestrol	Weight gain in children	2010
Cellular cardiac patch	Repair of congenital heart defects	2010
Aspirin vs. low molecular weight heparin	Stroke	2010
Sildenafil	Single ventricle heart disease postoperatively	2010
Tissue plasminogen activator (tPA)	Stroke and deep vein thrombosis	2010
Aesculon (noninvasive) cardiac monitor for children	Cardiac monitoring in emergency or intensive care unit setting	2010
Beta blocker vs. other meds	Heart failure	2010
Topiramate	Preventing brain injury in children undergoing congenital heart surgery	2010
Topical timolol	Infantile cutaneous hemangioma	2010
Singular	Safety in children with asthma and allergies	2010
Antipseudomonas antibodies	Pseudomonas infections	2010
Metformin	Polycystic ovary disease in adolescents	2010
Chloroprocaine	Pain in neonates	2007
Over-the-counter cold preparations: Chlorpheniramine Diphenhydramine Pseudoephedrine	Allergies or allergic rhinitis	2007 and 2010
Albendazole	<i>Giardia</i> infection (intestinal infection 06)	2005
Cefuroxime	Infections in children with sickle cell anemia	2005
Amantadine	Influenza	2005
Rimantadine	Influenza	2005
Dexamethasone	Allergic and ophthalmology disorders	2004
Epinephrine	Intraosseus/endotracheal infusion for resuscitation	2004
Fluconazole	Candidiasis, Cryptococcal meningitis, BMT prophylaxis	2004
Mebendazole	Intestinal worm infection	2004
Metronidazole	<i>Clostridium difficile</i> and <i>Giardia</i>	2005
Trazodone	Sleep disorders	2005

[Back to Top](#)